Weight loss before weight loss surgery in patients with fatty liver

Comparing effects of weight loss by Liraglutide 3.0 mg with conventional liver fasting in non-alcoholic fatty liver disease before bariatric surgery - Weight loss under Liraglutide 3.0mg

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-000220-19-AT

Enrollment

Registered

2020-03-24

Start date

2020-09-24

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and NAFLD can increase the risk and complexity of bariatric surgery up to 20%. Reducing the weight and liver size before bariatric surgery improves the operation area and reduces complications after the procedure.

Interventions

Trade Name: Saxenda Pharmaceutical Form: Solution for injection INN or Proposed INN: LIRAGLUTIDE CAS Number: 204656-20-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Con

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI > 40 kg/m2, NAFLD-diagnosis, Age: 18-60 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 62 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Type 1 Diabetes, liver cirrhosis, medication that cause weight loss or gain, use of GLP-1-Analoga or DPPIV-inhibitor

Design outcomes

Primary

Measure	Time frame
Main Objective: weight loss before bariatric surgery ;Secondary Objective: liver size reduction;Primary end point(s): weight loss before bariatric surgery ;Timepoint(s) of evaluation of this end point: after 12 weeks	—

Secondary

Measure	Time frame
Secondary end point(s): liver size reduction;Timepoint(s) of evaluation of this end point: after 12 weeks	—

Countries

Austria

Contacts

Public ContactSophie Maierhofer

Karl Landsteiner institute for obesity and metabolism

sophie.m.maierhofer@gmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026